Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies

We conducted a post hoc analysis in seropositive patients who were negative or borderline for functional neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline from a phase 1, 2, and 3 trial of casirivimab and imdevimab (CAS+IMD) treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hooper, Andrea T., Somersan-Karakaya, Selin, McCarthy, Shane E., Mylonakis, Eleftherios, Ali, Shazia, Mei, Jingning, Bhore, Rafia, Mahmood, Adnan, Geba, Gregory P., Dakin, Paula, Weinreich, David M., Yancopoulos, George D., Herman, Gary A., Hamilton, Jennifer D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765482/
https://www.ncbi.nlm.nih.gov/pubmed/36255239
http://dx.doi.org/10.1128/mbio.01699-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765482/
https://www.ncbi.nlm.nih.gov/pubmed/36255239
http://dx.doi.org/10.1128/mbio.01699-22

Ejemplares similares